AlloVir 관리

관리 기준 확인 3/4

AlloVir CEO는 Diana Brainard, May2021 에 임명되었습니다 의 임기는 3.5 년입니다. 총 연간 보상은 $ 6.06M, 10.3% 로 구성됩니다. 10.3% 급여 및 89.7% 보너스(회사 주식 및 옵션 포함). 는 $ 188.17K 가치에 해당하는 회사 주식의 0.31% 직접 소유합니다. 188.17K. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 4.3 년입니다.

주요 정보

Diana Brainard

최고 경영자

US$6.1m

총 보상

CEO 급여 비율	10.3%
CEO 임기	3.5yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

CEO 보상 분석

Diana Brainard 의 보수는 AlloVir 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$100m
Jun 30 2024	n/a	n/a	-US$140m
Mar 31 2024	n/a	n/a	-US$180m
Dec 31 2023	US$6m	US$623k	-US$190m
Sep 30 2023	n/a	n/a	-US$169m
Jun 30 2023	n/a	n/a	-US$167m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$9m	US$605k	-US$169m
Sep 30 2022	n/a	n/a	-US$189m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$185m
Dec 31 2021	US$15m	US$365k	-US$172m
Sep 30 2021	n/a	n/a	-US$139m
Jun 30 2021	n/a	n/a	-US$117m
Mar 31 2021	n/a	n/a	-US$91m
Dec 31 2020	US$597k	n/a	-US$70m

보상 대 시장: Diana 의 총 보상 ($USD 6.06M )은 US 시장( $USD 646.00K ).

보상과 수익: Diana 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Diana Brainard (53 yo)

3.5yrs

테뉴어

US$6,056,943

보상

Dr. Diana M. Brainard, MD., served as an Entrepreneur Partner at MPM Asset Management, L.L.C. since 2024. She served as an Executive Partner and Entrepreneur at MPM Asset Management, L.L.C. till December 2...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Hallal	Executive Chairman of the Board	6.2yrs	US$347.00k	2.45% $ 1.5m
Diana Brainard	CEO & Director	3.5yrs	US$6.06m	0.31% $ 188.2k
Vikas Sinha	President	5.8yrs	US$2.94m	0.85% $ 520.7k
Edward Miller	General Counsel & Secretary	5.8yrs	US$1.89m	0.38% $ 229.6k
Brett Hagen	Chief Accounting Officer	5.8yrs	데이터 없음	0.012% $ 7.6k
Ann Leen	Chief Scientific Officer	11.8yrs	데이터 없음	데이터 없음
Cintia Piccina	Chief Commercial Officer	1.4yrs	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: ALVR 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Hallal	Executive Chairman of the Board	6.2yrs	US$347.00k	2.45% $ 1.5m
Diana Brainard	CEO & Director	4.3yrs	US$6.06m	0.31% $ 188.2k
Vikas Sinha	President	5.8yrs	US$2.94m	0.85% $ 520.7k
John Mellors	Member of the Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Malcolm Brenner	Independent Non-Executive Director	12.8yrs	US$196.28k	0.20% $ 122.4k
Jeffrey Bornstein	Independent Non-Executive Director	4.3yrs	US$211.78k	0.066% $ 40.2k
Michael Boeckh	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
John DiPersio	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Anil Chandraker	Member of Scientific Advisory Board	1.8yrs	데이터 없음	데이터 없음
Morana Jovan-Embiricos	Independent Non-Executive Director	5.5yrs	US$209.28k	8.65% $ 5.3m
Shawn Tomasello	Independent Director	2.7yrs	US$200.73k	0.031% $ 18.7k
Juan Vera	Non-Executive Director	10.8yrs	US$187.00k	2.08% $ 1.3m

4.3yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: ALVR 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

AlloVir 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

High number of new directors

CEO & Director notifies of intention to sell stock

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

Recent updates

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

Kalaris Therapeutics, Inc. entered into an Agreement and Plan of Merger to acquire AlloVir, Inc. (NasdaqCM:ALVR) in a reverse merger transaction.

New minor risk - Share price stability

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

High number of new directors

Independent Non-Executive Director notifies of intention to sell stock

Insider recently sold US$447k worth of stock

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Insider notifies of intention to sell stock

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth